Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial?

Journal of Urology

Volumn 175, Issue 3, 2006, Pages 934-938

  Grover, Steven ^a,b,d   Lowensteyn, Ilka ^a,b,d   Hajek, David ^c,d   Trachtenberg, John ^c,d   Coupal, Louis ^a,b,d   Marchand, Sylvie ^a,b,d  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Finasteride; Prevention and control; Prostatic neoplasms; Risk assessment

Indexed keywords

FINASTERIDE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PREVENTION; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; CLINICAL TRIALS; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, THEORETICAL; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TIME FACTORS;

EID: 32044457933     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)00424-6     Document Type: Article

References (20)

1. A. Jemal, L.X. Clegg, E. Ward, L.A. Ries, X. Wu, P.M. Jamison Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival Cancer 101 2004 3
2. U. S. Department of Health and Human Services, National Institutes of Health. Available at http://seer.cancer.gov/faststats/html/dev_prost.html. 2005 SEER database accessed at National Cancer Institute public web site, February 28, 2005
3. B. Djavan, A. Zlotta, C. Schulman, P. Teillac, P. Iversen, L.B. Gibod Chemotherapeutic prevention studies of prostate cancer J Urol 171 2004 S10 part 2
4. G.J. Gormley, E. Stoner, R.C. Bruskewitz, J. Imperato-McGinley, P.C. Walsh, J.D. McConnell The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group N Engl J Med 327 1992 1185
5. J.D. McConnell, C.G. Roehrborn, O.M. Bautista, G.L. Andriole Jr., C.M. Dixon, J.W. Kusek The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 349 2003 2387
6. R.K. Ross, L. Bernstein, R.A. Lobo, H. Shimizu, F.Z. Stanczyk, M.C. Pike 5-alpha-reductase activity and risk of prostate cancer among Japanese and US while and black males Lancet 339 1992 887
7. I.M. Thompson, P.J. Goodman, C.M. Tangen, M.S. Lucia, G.J. Miller, L.G. Ford The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215
8. P.C. Albertsen, D.G. Fryback, B.E. Storer, T.F. Kolon, J. Fine Long-term survival among men with conservatively treated localized prostate cancer JAMA 274 1995 626
9. N.F. Col, R.J. Goldberg, R.K. Orr, J.K. Erban, J.M. Fortin, R.T. Chlebowski Survival impact of tamoxifen use for breast cancer risk reduction projections from a patient-specific Markov model Med Decis Making 22 2002 386
10. J.M. Inadomi Decision analysis and economic modelling a primer Eur J Gastroenterol Hepatol 16 2004 535
11. S.A. Grover, L. Coupal, H. Zowall, R. Rajan, J. Trachtenberg, M. Elhilali The clinical burden of prostate cancer in Canada forecasts from the Montreal Prostate Cancer Model CMAJ 162 2000 977
12. S.A. Grover, L. Coupal, H. Zowall, R. Rajan, J. Trachtenberg, M. Elhilali The economic burden of prostate cancer in Canada forecasts from the Montreal Prostate Cancer Model CMAJ 162 2000 987
13. G.L. Andriole, H.A. Guess, J.I. Epstein, H. Wise, D. Kadmon, E.D. Crawford PLESS Study Group Proscar Long-term Efficacy and Safety Study Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer results of a randomized, double-blind, placebo-controlled clinical trial Urology 52 1998 195
14. P.T. Scardino The prevention of prostate cancer-the dilemma continues N Engl J Med 349 2003 297
15. C.G. Roehrborn Prevention of prostate cancer with finasteride N Engl J Med 349 2003 1569
16. W.A. Sakr, G.P. Haas, B.F. Cassin, J.E. Pontes, J.D. Crissman The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients J Urol 150 1993 379
17. D.M. Smith, W.M. Murphy Histologic changes in prostate carcinomas treated with leoprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation Cancer 73 1994 1472
18. D.G. Bostwick Prostatic adenocarcinoma following androgen deprivation therapy the new difficulty in histologic interpretation Anat Pathol 3 1998 1
19. M.A. Rubin, P.W. Kantoff Effect of finasteride on risk of prostate cancer how little we really know J Cell Biochem 91 2004 478
20. H. Lepor, W.O. Williford, M.J. Barry, M.K. Brawer, C.M. Dixon, G. Gormley Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia N Engl J Med 335 1996 533